Gilead Sciences walks into its Q1 2026 results — scheduled for after the close on April 30 — with a notable tension: short interest has risen sharply over the past month, yet the Street remains firmly bullish and a meaningful regulatory catalyst landed just a day before the print.
The most striking shift in positioning is the pace at which shorts have rebuilt. Short interest has climbed nearly 24% over the past 30 days to 1.8% of the free float — not a crowded level by any measure, but the speed of accumulation stands out. Around April 23, roughly 1.3 million shares were added in a single session, pushing the notional short position past 22.7 million shares. The borrow market, however, remains entirely relaxed. Cost to borrow is running at just 0.40%, actually down around 17% over the month, and availability is loose — with utilization at a fraction of even its own 52-week high of 2.34%. Shorts are building incrementally, but nobody is scrambling to find stock to borrow. Options reinforce the idea that positioning is only mildly cautious: the put/call ratio is 0.57, barely above its 20-day average of 0.54 and well below the 52-week high of 1.28. Hedging activity is present but contained.
The Street's directional tilt is clearly bullish, with 17 buy-rated analysts and a mean price target of $158, implying roughly 23% upside from the current $128.84. Morgan Stanley raised its target to $175 earlier this month while maintaining Overweight, and Citigroup followed a few days later, lifting to $165 on a maintained Buy. Both moves came after the stock had already slipped from its highs — a signal that key banks are adding conviction into weakness rather than chasing. The sole meaningful dissenter in recent coverage is RBC Capital at Sector Perform, with a $118 target sitting below current levels. Valuation gives the bulls some comfort too: the P/E has drifted lower over the past 30 days to around 14.5x, while EV/EBITDA has nudged slightly higher to 10.3x — a profile that reads as reasonably priced for a large-cap biotech with durable cash flows. Factor scores flag a standout dividend rank in the 99th percentile, though the dividend history in the snapshot is stale and should not be treated as current guidance.
The regulatory picture added a fresh piece of the puzzle on April 29. The FDA accepted a new drug application for BIC/LEN, Gilead's daily oral HIV treatment combining bictegravir and lenacapavir. That's a meaningful pipeline step for a franchise that bulls point to as the core long-term growth driver — and bears counter is facing intensifying competition and patent-cliff risk. The bear case also leans on the company's reliance on hepatitis and HIV revenues and the drag from ongoing acquisitions and impairments. Neither side is sitting quietly into earnings.
Insider activity over the past 90 days leans toward selling, with the CEO, CFO, and Chief Commercial Officer all registering open-market sales in March and April — including a $1.4 million sale by Daniel O'Day in late March. Significance scores on these trades are low (2 out of 10), consistent with routine plan-driven activity rather than a directional signal. Net insider activity over 90 days is modestly positive in shares terms — awards and vesting flows outweigh the open-market sales — but the dominant visible activity has been selling at prices between $137 and $149, well above where the stock now trades at $128.84.
The recent earnings reaction history adds a cautionary data point. At the last quarterly print in April, the stock fell 4.4% on the day. The prior release in February produced a 2.7% gain, which held over five days. The setup this time includes a stock already down 3% on the week and 4% over the past month, so some of the negative sentiment may already be reflected. Peer pressure has been widespread: REGN dropped 6.2% on the day and is off 8.1% for the week, and VRTX lost 1.6% on Wednesday, suggesting broader sector caution rather than Gilead-specific selling. AMGN and ABBV diverge — AbbVie actually gained 3.1% Wednesday, offering a reminder that stock-specific catalysts dominate at the individual company level during earnings season.
The Q1 print and any commentary on the BIC/LEN NDA timeline are the two variables the market is watching most closely at the close today.
See the live data behind this article on ORTEX.
Open GILD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
